Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Second Look: Discussing the recent FDA approval and potential of Takeda's FRUZAQLA (fruquintinib) in previously treated metastatic colorectal cancer patients

Ticker(s): TAK

Who's the expert?

Medicial Oncologist with specialties in Hematology, Breast Cancer, Lymphoma & Chronic Leukemia, Multiple Myeloma, Lung & Thoracic Cancers
Directed the hematology/oncology fellowship training program at the Cleveland Clinic.
Extensive research expertise in the laboratory and clinical trials with the pharmaceutical industry and leading academic institutions

Interview Goal

To discuss the standard of care and potential of Takeda's FRUZAQLA (fruquintinib), an oral VEGFR inhibitor targeted therapy for adults with mCRC and the first new “chemotherapy-free treatment option approved for patients in the US regardless of biomarker status in more than a decade".

Do you want answers to these questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.